B&L'S CHIRON VISION PURCHASE COULD INCLUDE FDA-APPROVED REFRACTIVE LASER
This article was originally published in The Gray Sheet
Executive Summary
Bausch & Lomb's acquisition of Chiron Vision could put it in the U.S. refractive laser surgery market. Chiron Vision has a premarket approval application pending for a refractive excimer laser, and expects a decision from FDA by the end of the year. B&L announced a definitive agreement to buy Chiron Vision for $300 mil. cash on Oct. 20; the deal is expected to close in early 1998.